IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance
Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Jiang, Bin; Jiang, Hao; Shi, Hong-Xia; Huang, Xiao-Jun
刊名BLOOD
2012-11-16
120期:21
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
语种英语
WOS记录号WOS:000314049601310
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58968
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
作者单位Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Qian,Qin, Ya-Zhen,Lai, Yue-Yun,et al. Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance[J]. BLOOD,2012,120(21).
APA Jiang, Qian.,Qin, Ya-Zhen.,Lai, Yue-Yun.,Jiang, Bin.,Jiang, Hao.,...&Huang, Xiao-Jun.(2012).Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance.BLOOD,120(21).
MLA Jiang, Qian,et al."Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance".BLOOD 120.21(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
百度学术
百度学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
必应学术
必应学术中相似的文章
[Jiang, Qian]的文章
[Qin, Ya-Zhen]的文章
[Lai, Yue-Yun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。